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Abstract
Background: The CD4/CD8 ratio has been associated with the risk of AIDS and non-AIDS events. We describe
trends in immunological parameters in people who underwent a switch to monotherapy or dual therapy,
compared to a control group remaining on triple antiretroviral therapy (ART).
Methods: We included patients in Icona who started a three-drug combination ART regimen from an ART-naïve
status and achieved a viral load ≤ 50 copies/mL; they were subsequently switched to another triple or to a mono or
double regimen. Standard linear regression at fixed points in time (12-24 months after the switch) and linear mixed
model analysis with random intercepts and slopes were used to compare CD4 and CD8 counts and their ratio over
time according to regimen types (triple vs. dual and vs. mono).
Results: A total of 1241 patients were included; 1073 switched to triple regimens, 104 to dual (72 with 1 nucleoside
reverse transcriptase inhibitor (NRTI), 32 NRTI-sparing), and 64 to monotherapy. At 12 months after the switch, for
the multivariable linear regression the mean change in the log10 CD4/CD8 ratio for patients on dual therapy was −0.03
(95% confidence interval (CI) –0.05, –0.0002), and the mean change in CD8 count was +99 (95% CI +12.1, +186.3),
taking those on triple therapy as reference. In contrast, there was no evidence for a difference in CD4 count change.
When using all counts, there was evidence for a significant difference in the slope of the ratio and CD8 count between
people who were switched to triple (points/year change ratio = +0.056, CD8 = −25.7) and those to dual
regimen (ratio = −0.029, CD8 = +110.4).
Conclusions: We found an increase in CD8 lymphocytes in people who were switched to dual regimens
compared to those who were switched to triple. Patients on monotherapy did not show significant
differences. The long-term implications of this difference should be ascertained.
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Background
Long-term side effects of antiretroviral therapy (ART) drugs
have led to the introduction in clinical practice of nucleoside
reverse transcriptase inhibitor (NRTI)-sparing regimens as
double or monotherapy, and their use is now recommended
in specific populations according to international guidelines
[1, 2]. Indeed, based on the monitoring of surrogate markers
of ART efficacy, most of these unconventional regimens,
when used in switch studies, have been shown to have a
non-inferior virological efficacy and a good CD4 recovery
compared to standard triple drug-based therapy [3–8]. The
results of these studies were so encouraging that dual com-
binations are currently being tested in randomized clinical
trials of ART-naïve patients [9, 10]. The results of the GEM-
INI 1-2 international trials on ART-naïve patients with a
baseline plasma viremia < 500,000 copies/mL randomized to
receive either tenofovir/emtricitabine or lamivudine both
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combined with dolutegravir are also ongoing [11]. If dual
regimes are going to be proved non-inferior to triple com-
bination therapy in the ART-naïve population, a single tablet
of this dual regimen will likely be developed. Thus, as a con-
sequence of the publication of the results of these studies, in
order to save toxicities and resources, we could see a shift in
drug production and clinical use of dual therapies [12, 13].
However, it has been recently shown that virological
suppression and CD4 cell count fail to protect from the
major causes of death of persons living with HIV
(PLWHIV), which are mainly non-AIDS-related events, also
known as serious non-AIDS events (SNAEs) [14]. At
present, the best marker to evaluate the risk of developing
SNAEs has not been determined. Interestingly, the analysis
of the data of our and other cohorts have shown that, in
contrast with recent data from the Antiretroviral Therapy
Cohort Collaboration (ART-CC) [15], a low CD4/CD8 ratio
is a predictor of non-AIDS-related events independently
from CD4 cell count [16, 17], while other studies have
shown an association of this marker with non-AIDS-
defining cancers [18] or, more recently, with pulmonary
emphysema [19].
Therefore, we hereby aimed to compare CD4/CD8 ra-
tio changes in a group of patients who, in the presence
of undetectable plasma HIV viremia, were switched to a
protease inhibitor monotherapy (mono) or a dual ART,
to a control group who was switched to a standard triple
drug-based treatment.
Methods
Study design and participants
The Icona Foundation Study is a cohort of HIV-infected
patients; this study superseded the original I.Co.N.A.
(Italian Cohort of Antiretroviral-Naïve Patients) study (a
detailed description of this cohort is given elsewhere
[20]), recruiting HIV-positive patients when they are still
ART-naïve regardless of the reason. CD4 and CD8 cell
counts and viral load are measured every 4–6 months
together with other laboratory parameters (e.g., liver and
kidney function, lipids, etc.) as well as clinical and
therapy data. All patients signed consent forms to
participate in the Icona Foundation Study, locally in
each of the participating clinical sites, and the research
study protocol has been approved by local institutional
review boards. The accuracy of non-AIDS events
diagnoses is checked by both central and in situ
monitoring, by HIV Cohorts Data Exchange Protocol
(HICDEP) coding. Central monitoring is done every
6 months to check the accuracy of the data entered. A
data monitor goes to each center annually and controls
10–25% of the clinical charts. In case of discordances,
the percentage of checked clinical charts increases to
50%, according to the procedure of the D:A:D study, in
which Icona participates.
All analyses were restricted to patients in the cohort who
did the following: started a combination ART (cART) regi-
men including three antiretrovirals from being ART-naïve;
had reached a confirmed HIV RNA ≤ 50 copies/mL; had
switched to either another triple regimen or to double or
monotherapy for any reason and at any time after achieving
suppression, had maintained virological suppression after
12 months on this same regimen which had been switched
to and had in the time window [−3; +3] around 12 months
from the switch at least one CD4 and CD8 measurement
available (only the first switch episode after achieving sup-
pression was included). Those who switched to triple ther-
apies were considered as the control group in order to have
a more uniform population and to avoid, if possible, biases.
If more measurements were available in the defined
time window, the nearest to 12 months was selected.
We included only patients with a date of switch that
occurred after January 2006, because this was the first
year in which the switch to mono/dual therapy in people
with suppressed HIV RNA was introduced in clinical
practice in Italy. We also selected a subgroup of patients
for whom at least a CD4 and a CD8 count were available
in the window [−3; +3] around 24 months from the
switch and the same regimen and the virological
suppression were still maintained. Four patients who
switched to a dual therapy including maraviroc were
excluded from the analyses, as exposure to this drug is
believed to increase the CD8 count [21].
The follow-up was interrupted at the date of discon-
tinuation of at least one drug in the regimen started
after the switch or at the date of the first of two con-
secutive HIV RNA levels > 50 or at the date of the CD4/
CD8 ratio at 24 months, whichever occurred first.
During the follow-up, the total number of single viral
blips, where a blip is defined as (1) a single value of HIV
RNA ≥ 50 copies/mL followed by a value < 50 with no
treatment switch and (2) a single value of HIV RNA ≥
200 copies/mL followed by a value < 200, was evaluated
and described.
Statistical analyses
The characteristics of the study population at the time
of the switch, stratified by treatment strategy, were com-
pared using the non-parametric Kruskal-Wallis test for
continuous parameters and the chi-square test for cat-
egorical variables.
Endpoints of the analysis were the change in CD4/
CD8 ratio, in CD8, and in CD4 from the switch to 12
and 24 months. Multivariable linear regressions were
used to evaluate the association between endpoints and
type of regimen, adjusting for main confounders. A lin-
ear mixed model with random intercepts and random
slopes for repeated measurements of ratio, CD8, and
CD4 change was used to compare the course over time
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of these markers according to regimen strategies. The
follow-up started at the date of ART switch and ended at
first virological rebound defined by the first of two con-
secutive HIV RNA measures > 50 copies/mL or a stop/
change of at least one drug of the regimen or the date of
the last CD4/CD8 count at 24 months from the switch,
whichever came first. The sample size of the mono/dual
therapy group became too small after 24 months to yield
accurate estimates.
The comparison between mono/dual and triple switch
was controlled for a number of potential time-fixed con-
founders measured at the time of the switch or at previous
times: age, gender, nation of birth, mode of HIV transmis-
sion, hepatitis C virus (HCV) co-infection, AIDS diagnosis,
CD4 counts and HIV RNA at ART initiation, years of HIV
infection, duration of viral suppression before switch, CD4
and CD8 counts at switch, and reasons for switch. The ana-
lysis was not controlled for time-dependent confounders.
Results
Study population
A total of 1241 patients were included in the analysis;
1073 switched to triple regimens, 104 to dual regimens,
and 64 to monotherapy. Concerning the baseline regi-
mens, almost all patients were receiving tenofovir + emtri-
citabine, 935 (75.3%), while the third agents are described
in Additional file 1: Table S1.
Figure 1 presents a flowchart with the distribution of
the various regimens to which participants were switched.
No differences in age, gender, nationality, duration of
HIV infection, HCV co-infection, or virological condition
at the time of first starting ART were observed among the
three groups who switched to triple, mono, or dual ther-
apy (Table 1). The CD4 count before cART initiation was
more frequently lower than 350 and less frequently more
than 500 cells/uL in patients who switched to a triple regi-
men compared to those on mono or double therapy. The
median duration of the first line regimen and of viral sup-
pression before the switch was similar for the three
groups. The CD8 cell counts at the switch were similar,
while the median of the CD4/CD8 ratio and the CD4
count at the switch were slightly higher in patients who
switched to monotherapy. Patients who were switched to
a triple regimen were more likely to have acquired HIV
via heterosexual contacts and less frequently through
homosexual contacts and were more frequently in Centers
for Disease Control and Prevention (CDC) stage C com-
pared to patients with lower drug regimens.
The switch to monotherapy compared to those who
switched to triple or dual therapy less frequently was
made for simplification and more frequently for toxicity,
in particular, kidney toxicity (3.8% vs. 14.4%, p < 0.001).
The three groups of patients showed a similar length
of follow-up after the date of switch (22.1, 21.9, and 22.
7 months respectively for the triple, dual, and mono
regimens, p = 0.084). Over a median follow-up of
22 months (interquartile range (IQR) 21–24) the total
numbers of single blips of HIV RNA > 200 and > 50
copies/mL during the follow-up period were similar for
the three groups: 7.0% for the triple, 6.7% for the dual, and
5.9% for the mono regimen (p = 0.837) and 1.9%, 0%, and
0% (p = 0.120) respectively.
Univariable analysis: change from baseline to 12 and
24 months
At 12 months from the date of switching, patients on
the triple regimen showed a higher mean CD4/CD8 ra-
tio (log10) increase +0.12 vs. +0.04 (p = 0.017) compared
Fig. 1 Flow-chart of distribution of the various regimens to which participants were switched
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Table 1 Main characteristics of study population according to regimen started after switch
All study population Triple Dual Mono p value
Patients’ characteristics (n = 1241) (n = 1073) (n = 104) (n = 64) –
Male gender, n (%) 988 (79.6%) 853 (79.5%) 86 (82.7%) 49 (76.6%) 0.612
Age, median (IQR) 43 (36–50) 42 (35–50) 45 (38–51) 44 (38–49) 0.065
Mode of HIV transmission, n (%)
Heterosexual 534 (43.0%) 474 (44.2%) 40 (38.5%) 20 (31.3%) 0.025
Injection drug use 100 (8.1%) 92 (8.6%) 5 (4.8%) 3 (4.7%)
Men who have sex with men 533 (42.9%) 440 (41.0%) 54 (51.9%) 39 (60.9%)
Other/unknown 74 (6.0%) 67 (6.2%) 5 (4.8%) 2 (3.1%)
Migrants, n (%) 151 (12.2%) 136 (12.7%) 8 (7.7%) 7 (10.9%) 0.317
Previous AIDS event, n (%) 161 (130%) 152 (14.2%) 8 (7.7%) 1 (1.6%) 0.004
Years of HIV infection, median (IQR) 3.4 (1.6–6.3) 3.3 (1.6–6.3) 3.3 (1.6–6.5) 4.2 (2.1–6.1) 0.472
HCV Ab, n (%)
Negative 1057 (85.2%) 908 (84.6%) 88 (84.6%) 61 (95.3%) 0.197
Positive 120 (9.7%) 109 (10.2%) 10 (9.6%) 1 (1.6%)
Unknown 64 (5.1%) 56 (5.2%) 6 (5.8%) 2 (3.1%)
CD4 before cART start, n (%)
< 200 368 (29.7%) 334 (31.1%) 24 (23.1%) 10 (15.6%) 0.047
201–350 399 (32.2%) 344 (32.1%) 29 (27.9%) 26 (40.6%)
351–500 307 (24.7%) 258 (24.0%) 30 (28.9%) 19 (29.7%)
500+ 143 (11.5%) 116 (10.8%) 18 (17.3%) 9 (14.1%)
Missing 24 (1.9%) 21 (2.0%) 3 (2.8%) –
HIV RNA before cART start, n (%)
< 20,000 337 (27.2%) 279 (26.0%) 37 (35.5%) 21 (32.8%) 0.385
20,000–100,000 410 (33.0%) 358 (33.3%) 30 (28.9%) 22 (34.4%)
100,000–250,000 235 (18.9%) 207 (19.3%) 18 (17.3%) 10 (15.6%)
250,000+ 233 (18.8%) 208 (19.4%) 15 (14.4%) 10 (15.6%)
Missing 26 (2.1%) 21 (2.0%) 4 (3.9%) 1 (1.6%)
CD4 at switch, median (IQR)
< 350 219 (17.7%) 199 (18.6%) 14 (13.5%) 6 (9.4%) 0.008
350–500 285 (23.0%) 255 (23.8%) 23 (22.1%) 7 (10.9%)
500+ 737 (59.3) 619 (57.6%) 67 (64.4%) 51 (79.7%)
CD4 at switch, median (IQR) 554 (402–740) 547 (394–729) 600 (426–819) 614 (506–807) 0.012
CD8 at switch, median (IQR) 824 (600–1118) 832 (601–1121) 797 (587–1124) 768 (597–1009) 0.467
CD4/CD8 ratio at switch, median (IQR) 0.69 (0.45–0.98) 0.67 (0.44–0.97) 0.78 (0.51–1.10) 0.83 (0.58–1.09) 0.008
CD4/CD8 ratio at switch > = 1, n (%) 303 (24.4%) 256 (23.9%) 29 (27.9%) 18 (28.1%) 0.513
Months of antiretroviral exposure, median (IQR) 18 (9–34) 17 (8–35) 18 (12–36) 20 (12–31) 0.184
Months of viral suppression, median (IQR) 21 (11–39) 21 (10–39) 20 (12–37) 20 (13–34) 0.824
Reason for switch, n (%)
Toxicity 330 (26.6%) 294 (27.4%) 27 (26.0%) 9 (14.1%) < 0.001
Simplification 493 (39.6%) 407 (38.0%) 42 (40.4%) 44 (68.7%)
Patient’s decision 18 (1.5%) 17 (1.6%) 0 (0.0%) 1 (1.6%)
Other 387 (31.2%) 346 (32.2%) 31 (29.8%) 10 (15.6%)
Missing 13 (1.1%) 9 (0.8%) 4 (3.8%) 0 (0.0%)
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to patients on the dual therapy and +0.07 (p = 0.079)
compared to patients on the monotherapy (Table 2).
We found that 30.6% of patients on the triple regi-
men had a CD4/CD8 ratio ≥ 1 vs. 36.5% of patients
on the dual therapy and 35.9% of patients on the
monotherapy (p = 0.328).
The same comparison was performed after restricting
to 724 patients who had data at 24 months available
(622 triple, 57 dual, and 45 mono), and again in this ana-
lysis the triple regimens showed higher mean ratio in-
crease compared to the dual therapy patients (+0.17 vs.
+0.08, p = 0.024), but not compared to the monotherapy
patients (+0.12, p = 0.786) (Table 3). However, the
percentage of patients with ratio ≥ 1 at 24 months was
still not different among patients who switched to triple,
dual, and mono regimens (34.4%, 34.3%, 40.0%
respectively, p = 0.696).
Interestingly, the mean change of CD4 count from
baseline to 12 months was not different between the
groups: +66 for the switch to triple, +86 for the switch
to dual, and +59 for the switch to mono at 12 months
and +95, +89, and +141 at 24 months respectively. Con-
versely, the mean change of CD8 count was different
among the three groups. In patients who were switched
to dual therapy, at 12 months the mean change was +62
cells/mm3, and it was +34 in those who switched to
monotherapy, while in the group who switched to triple
therapy the mean change was −28 cells. This difference
was observed and again was more pronounced at
24 months: patients on the triple regimen had a mean
reduction of CD8 of −45 cells, patients switched to the
dual regimen presented a mean increase of +28 cells,
and there was an increase of +101 for those who
switched to the monotherapy.
Factors associated with the change of CD4/CD8 ratio and
of CD8: simple linear regression analysis of marker change
In the multivariable analysis, the type of switch strategy
was associated with the change in CD4/CD8 ratio from
the switch to (1) 12 months and (2) 24 months, when ana-
lyzed as continuous outcomes (Table 4). After adjusting
for age, gender, mode of HIV transmission, nationality,
previous AIDS event, years of HIV infection, HCV co-
infection, HIV RNA and CD4 at cART initiation, CD4
and CD8 count at switch, reason for switch, and months
of viral suppression before switch, patients on dual
therapy showed a gain in log10 ratio at 12 months and at
24 months lower than that seen in patients on the triple
regimen. Patients switched to monotherapy showed a
change not significantly different compared to the refer-
ence group on triple therapy.
From multivariable models with the change of CD8 at 12
and 24 months as the outcome, patients on dual therapy
showed a higher mean change than that seen in people on
triple therapy. Patients on monotherapy showed a mean
change of CD8 not different compared to that for subjects
on the triple regimen. No difference was found for the CD4
change between the two types of regimen.
Mixed models
Our 1241 patients contributed 6528 CD4/CD8 ratio mea-
surements over a period of 24 months. A median number
of 5 (IQR 4–7) CD4/CD8 ratio values/patient were re-
corded. In the univariable analysis, the estimate of the over-
all increase in the log10 ratio was +0.040 points/year (95%
confidence interval (CI) +0.036, +0.044; p < 0.001). Points/
year change in the log10 ratio were +0.042 (95% CI +0.037,
+0.047) for patients on the triple regimen and –0.013 (95%
CI –0.029, −0.003) for subjects who switched to dual
Table 2 Comparison of mean value and standard deviation (SD) of CD4/CD8 ratio, CD8, and CD4 at switch and 12 months after
switch between triple and dual and between triple and monotherapy
Triple (N = 1073) Dual (N = 104) p value Mono (N = 64) p value
CD4/CD8 ratio
At switch, mean (SD) 0.76 (0.46) 0.85 (0.51) 0.054 0.89 (0.50) 0.009
12 months after switch, mean (SD) 0.88 (0.63) 0.89 (0.52) 0.666 0.97 (0.55) 0.091
Change, mean (SD) +0.12 (0.48) +0.04 (0.15) 0.004 +0.07 (0.21) 0.079
CD8 cell count
At switch, mean (SD) 912 (454) 924 (504) 0.778 825 (345) 0.220
12 months after switch, mean (SD) 884 (506) 986 (558) 0.197 860 (410) 0.576
Change, mean (SD) −28 (471) +62 (321) 0.010 +34 (222) 0.096
CD4 cell count
At switch, mean (SD) 588 (289) 652 (320) 0.039 646 (260) 0.022
12 months after switch, mean (SD) 654 (294) 738 (338) 0.012 705 (223) 0.017
Change, mean (SD) +66 (184) +86 (180) 0.251 +59 (197) 0.757
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therapy (Table 5). After adjustment for baseline values in
the intercept, changes for the triple regimen were +0.056
(95% CI +0.047, +0.064), while for the dual regimen they
were −0.029 (95% CI –0.056, –0.002). There was evidence
for a significant difference in slope between the triple and
dual regimens (interaction test, p = 0.033).
The overall observed trend for CD8 count was −7.2
cells/year (95% CI –31, +17; p = 0.559). In the univari-
able analysis, subjects on the triple regimen showed a
change of −22.2 (95% CI –48.0, +3.7) CD8 cells/year, while
patients on dual therapy had a mean change of +114.9
(95% CI –32.9, +197.0) CD8 cells/year. In the multivari-
able analysis the CD8 counts of patients on the triple regi-
men were reduced by −25.7 (95% CI –51.6, +0.28), while
CD8 counts for the dual regimen showed a significant in-
crease of +110.4 cells/year (95% CI +27.3, +193.6). There
was evidence for a significant difference in slope between
the triple and dual regimens (interaction test p = 0.009).
Neither the CD4/CD8 ratio nor the CD8 count showed a
significant linear trend in the group of patients on
monotherapy.
Discussion
The main result of our study is that when comparing
three groups of patients undergoing different switch
strategies in the presence of undetectable HIV RNA,
those who were switched to dual regimens showed a
stabilization of the CD4/CD8 ratio, while the CD4/C8
ratio of those who were switched to a three-drug-based
regimen continued to improve after the switch. This
result appears not to be due to the CD4 increase, since
no significant difference in the CD4 count trajectory
between the two groups could be detected, but to a spe-
cific increase in CD8 lymphocyte count in participants
switching to dual therapy. More importantly, because
CD4 count continued to increase and plasma viral load
continued by analysis design to be undetectable in all
subjects, this difference in the ratio would possibly go
undetected by standard monitoring of HIV RNA and
CD4 count alone.
A lower CD4/CD8 ratio can be interpreted as a meas-
ure of dysregulation of a patient’s immune system,
known as immunological risk phenotype, in the general
population and has been clearly associated with a higher
risk of AIDS and non-AIDS events in HIV-infected
patients [16, 17]. Therefore, more and more frequently,
in people with undetectable HIV RNA, chronic inflam-
mation is becoming an important long-term prognosis
issue, and measuring the CD4/CD8 ratio could clinically
represent a reliable tool to monitor this phenomenon.
Indeed, despite successful cART, there is evidence for
continuous quantitative, qualitative, and functional de-
fects in the CD8 compartments, although some of these
defects in some cases could be reversed by early treat-
ment [22]. However, during chronic HIV infection, per-
ipheral CD8 T cells persistently maintain several defects
which are reflected in continuous maintenance of the
immune activation parameters. It has been shown that
this activation contributes to immunologic exhaustion,
hyporesponsiveness of specific T cells, and perturbations
in the T cell receptor repertoire. However, reasons for
the persistence of elevated CD8 T cells during treatment
have not been fully elucidated. Long-term therapy usu-
ally determines a significant CD4 recovery, contrasting
with, despite a decrease from baseline, persistently
elevated CD8 T cell counts [23]. Previous analyses of co-
hort data have shown that elevated CD8 T lymphocytes
at cART initiation were associated with a poor increase
in the CD4 T cell count, even if the studies showed no
data on CD8 activation [22, 23].
Table 3 Comparison of mean value and standard deviation (SD) of CD4/CD8 ratio, CD8, and CD4 at switch and 24 months after
switch between triple and dual and between triple and monotherapy in two different regimens in 724 patients who had available
data at 24 months
Triple (N = 622) Dual (N = 57) p value Mono (N = 45) p value
CD4/CD8 ratio
At switch, mean (SD) 0.76 (0.45) 0.80 (0.37) 0.167 0.90 (0.48) 0.025
24 months after switch, mean (SD) 0.93 (0.71) 0.88 (0.43) 0.824 1.02 (0.50) 0.105
Change, mean (SD) +0.17 (0.58) +0.08 (0.19) 0.024 +0.12 (0.22) 0.786
CD8 cell count
At switch, mean (SD) 912 (458) 882 (471) 0.396 812 (363) 0.173
24 months after switch, mean (SD) 867 (451) 911 (411) 0.337 913 (575) 0.870
Change, mean (SD) −45 (401) +28 (256) 0.017 +101 (404) 0.012
CD4 cell count
At switch, mean (SD) 588 (285) 614 (269) 0.402 654 (274) 0.040
24 months after switch, mean (SD) 683 (294) 703 (272) 0.285 795 (332) 0.006
Change, mean (SD) +95 (181) +89 (175) 0.943 +141 (229) 0.205
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Indeed, in Caby’s study, 50% of individuals with a ratio
< 1 despite a normalized CD4 count (> 500 cells/uL) still
displayed a CD8 count that remained abnormally high
(> 1000 cells/uL) [24]. Moreover, only individuals with a
ratio ≥ 1.5 achieved an apparently normal median CD8
count when compared to healthy HIV-seronegative
individuals [24]. Furthermore, after 8 years of suppres-
sive cART, only one-third of patients of the French Hos-
pital Database on HIV cohort achieved CD4/CD8
restoration [23]. Encouragingly, Saracino et al. have
shown that patients with more than 15 years of cART
had a progressive increase in the CD4/CD8 ratio which
never reached a plateau, but patients included in that
analysis were receiving triple therapy [25]. Our data sug-
gest that treating patients with less than three drugs
might lead to a stop of this virtuous trend.
What could explain the CD8 increase observed in our
patients who were switched to dual therapies? One
possible explanation is that two drugs could not sup-
press HIV as well as three drugs can. A small residual
viremia, probably in lymphoid tissues, could thus trigger
the production of proinflammatory and/or homeostatic
cytokines that, in turn, would stimulate and/or maintain
CD8 T cell proliferation/activation. In our analysis,
everybody had an HIV RNA ≤ 50 copies, but we could
not create a finer classification below this threshold with
the available information on the assays used. In addition,
we have shown that viral blips > 50 copies/mL were rare,
and their rate of occurrence was similar between the
mono, dual, and triple regimen groups, while those
> 200 copies/mL were actually more frequent among
those who were in the triple regimen. Moreover, it
has been previously described that even more
sophisticated markers of residual HIV replication,
such as HIV -DNA, did not differ between patients
switched to dual or monotherapy compared to those
continuing triple therapy [26, 27]. However, it is
possible that viral replication restarts in lymphoid
tissues, and it could be detected by new sophisti-
cated techniques like digital droplet polymerase
chain reaction (PCR) or functional virological assays
[28] or by analyzing cells resident in those anatomic
districts—assays that typically are not available in
routine clinical studies. Indeed, recent data from the
Collaboration of Observational HIV Epidemiological
Research in Europe (COHERE) have shown that, in
HIV controllers, the decrease of the ratio and the in-
crease in CD8 lymphocyte counts preceded by 5 years
the end of virological control. Moreover, CD8
lymphocyte counts increased significantly in those
who experienced loss of virological control, whereas
they remained stable in the other groups [29]. Cur-
rently it is very unlikely to see randomized clinical
trials which last longer than 144 weeks, which is too
short a time to verify the COHERE observation in
the context of randomized data. Moreover, very
rarely are CD8 lymphocyte count data reported in
clinical trials. Helleberg et al. have shown that in pa-
tients receiving cART for 10 years a value of CD8
lymphocyte count which stays above 1500 cells/uL is
Table 4 Two separate multivariable linear models to test the
association of the dependent variable with the type of regimen
started after switch. Every model is adjusted for: age, gender,
mode of HIV transmission, Italian nationality, previous AIDS
event, years of HIV infection, HCV co-infection, HIV RNA and
CD4 at cART initiation, CD4 and CD8 count at switch, reason for
switch, months of viral suppression
a) Multivariable linear regression with changes at 12 months
Coefficient 95% CI p value
Dependent variable: CD4/CD8 ratio (log10) change at 12 months
Regimen after switch
Triple Ref.
Dual −0.03 −0.05, −0.0002 0.049
Mono −0.007 −0.04, +0.03 0.685
Dependent variable: CD8 change at 12 months
Regimen after switch
Triple Ref.
Dual +99.2 +12.1, +186.3 0.026
Mono +24.7 −84.1, +133.5 0.656
Dependent variable: CD4 change at 12 months
Regimen after switch
Triple Ref.
Dual +28.8 −8.0, +65.6 0.125
Mono −4.8 −50.8, +41.1 0.837
b) Multivariable linear regression with changes at 24 months
Coefficient 95% CI p value
Dependent variable: CD4/CD8 ratio (log10) change at 24 months
Regimen after switch
Triple Ref.
Dual −0.06 −0.10, −0.02 0.003
Mono −0.01 −0.06, +0.03 0.549
Dependent variable: CD8 change at 24 months
Regimen after switch
Triple Ref.
Dual +192.0 −8.4, +392.3 0.060
Mono +29.3 −200.7, +259.4 0.802
Dependent variable: CD4 change at 24 months
Regimen after switch
Triple Ref.
Dual +2.1 −48.9, +53.1 0.936
Mono +51.2 −7.3, +109.8 0.086
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associated with increased non-AIDS-related mortality
(mortality rate ratio 1.82; CI 1.09–3.22) [22].
The changes in ratio and in CD8 were not detected in
subjects switched to monotherapy. Indeed, although
there was a trend in the univariable analysis, it was not
confirmed with the multivariable linear regression and
mixed models analysis. One possible explanation could
be the lower number of subjects who were switched to
monotherapy, but another could be that their better im-
munological profile was definitively better at baseline.
We are well aware of the limitations of our study.
First, among dual therapies we could not examine
protease inhibitor (PI) and integrase strand transfer
inhibitor (INSTI)-based combinations separately (not
many people received dolutegravir either); second, a
median follow-up of 2 years could not allow us to
evaluate either the persistence of this phenomenon or
the impact of the strategies on the onset of non-
AIDS events; third, we did not have more detailed
immunological data than the counts themselves, and
it would be extremely relevant to stratify the analysis
according to specific CD8 subpopulations and CD38/
HLDR+ expression. Finally, since our analysis is retro-
spective and non-randomized, it only accounts for
measured fixed confounders at the time of the
therapy switch. Thus, we cannot rule out bias being
introduced by unmeasured confounders or time-
dependent confounders that have not been appropri-
ately controlled for. In particular, even in the con-
trolled setting of undetectable HIV RNA, patients
switching to a reduced drug regimen (less than three)
instead of another three-drug regimen might be deter-
mined by the factors that we did not measure.
After more than 20 years since the introduction of
cART because of the use in clinic of new potent and bet-
ter tolerated drugs, there is now interest in reassessing
the ideal number of antiretroviral drugs which need to
be prescribed. In the absence of data from randomized
studies, our results appear to be relevant to this debate.
Current research on the clinical effectiveness of dual
cART regimens is focused on non-inferiority of the viro-
logical outcome and on saving toxicity due to reducing
drugs in the regimens. Nevertheless, it is possible that
dual regimens have an unfavorable impact on the CD4/
CD8 ratio, and this possibility must be thoroughly inves-
tigated before implementing novel drug treatment
strategies including less than three drugs.
At present, there is evidence supporting CD8 count
monitoring as optional in patients with satisfactory
virological and immunological control during ART [30],
and this is currently taken into account by international
guidelines [2]. However, immunological monitoring
based only on the predictive role of a low CD4 count on
the risk of developing clinical events may underestimate
the role of the CD8 count as a surrogate of a proinflam-
matory state.
Conclusions
In this cohort of treated and virologically suppressed HIV-
positive patients, the CD4/CD8 ratio continued to increase
Table 5 Unadjusted and adjusted coefficients from linear mixed model regression analysis to test the association between the
dependent variable and type of regimen started after switch. Every model is adjusted for: age, gender, mode of HIV transmission,
Italian nationality, previous AIDS event, years of HIV infection, HCV co-infection, HIV RNA and CD4 at cART initiation, CD4 and CD8
count at switch, reason for switch, months of viral suppression
Unadjusted coefficient 95% CI Adjusted coefficient 95% CI
CD4/CD8 ratio (log10)
Regimen after switch
Triple +0.042 (+0.037, +0.047) +0.056 (+0.047, +0.064)
Dual −0.013 (−0.029, −0.003) −0.029 (−0.056, −0.002)
Mono −0.013 (−0.030, +0.005) −0.011 (−0.044, +0.021)
CD8, cells/mm3
Regimen after switch
Triple −22.2 (−48.0, +3.7) −25.7 (−51.6, +0.28)
Dual +114.9 (−32.9, +197.0) +110.4 (+27.3, +193.6)
Mono +73.5 (−25.4, +172.5) +64.7 (−35.6, +165.0)
CD4, cells/mm3
Regimen after switch
Triple +46.7 (+40.3, +53.1) +45.2 (+30.7, +59.6)
Dual +7.6 (−13.5, +28.8) +32.1 (−13.1, +77.3)
Mono +23.6 (−1.40, +48.7) +18.0 (−36.9, +72.9)
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in those who switched to triple regimens, whereas it stabi-
lized due to a selective increase in CD8 cells among those
who switched to dual therapy. Our results suggest that, be-
fore dual therapy may eventually become a standard of care
in patients with HIV infection, the impact of this strategy
on the immune system should be further assessed and
considered.
Additional file
Additional file 1: Table S1. Baseline third drugs in patients who
switched to triple, dual, or monotherapy. (DOCX 12 kb)
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